PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9885692

Brain attack: the multifaceted potential for action.

F Lateef·V Anantharaman
View original source ↗Export metadata ↓

Abstract

BACKGROUND: Stroke is the number 3 killer in Singapore and a common contributor to morbidity statistics. This study was done to look at the profile of patients with acute stroke presenting to the Emergency Department, Singapore General Hospital, from 1 October to 31 November 1996. The data will help plan and guide future early interventional trials as well as look into possible areas of improvement in the multidisciplinary approach to stroke. METHOD: This is a retrospective study and patients records were traced using ICD-9 codes. A total of 309 patients were identified for the period of review; of this, the records of 240 patients were obtained (77.7%). RESULTS: The results revealed that local stroke patients are young (two-thirds are < 70 years) and live in high-rise accommodation (84.2%) with their families. The predominant risk factor was hypertension (80%) and weakness was the most common presentation (25%). Stroke patients are presenting at a later stage (only 16.7% presented within 6 hours of onset) and the average length of hospital stay was between 10 and 12 days. CONCLUSION: This study identified the multiple measures at various stages of the stroke chain, required to build up a concerted effort against Brain Attack.

Explore related subjects

Acute DiseaseAgedCerebrovascular DisordersFemaleHumansHypertensionMaleMiddle AgedRetrospective StudiesRisk FactorsSingaporeSocioeconomic FactorsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F Lateef, V Anantharaman. 1998. Brain attack: the multifaceted potential for action.. https://pubmed.ncbi.nlm.nih.gov/9885692/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Loss of noradrenaline transporter sites in frontal cortex of rats with acute (ischemic) liver failure.

There is increasing evidence that central noradrenaline (NA) transport mechanisms are implicated in the central nervous system complications of acute liver failure. In order to assess this possibility, binding sites for the high affinity NA transporter ligand [3H]-nisoxetine were measured by quantitative receptor autoradiography in the brains of rats with acute liver failure resulting from hepatic devascularization and in appropriate controls. In vivo microdialysis was used to measure extracellular brain concentrations of NA. Severe encephalopathy resulted in a significant loss of [3H]-nisoxetine sites in frontal cortex and a concomitant increase in extracellular brain concentrations of NA in rats with acute liver failure. A loss of transporter sites was also observed in thalamus of rats with acute liver failure. This loss of NA transporter sites could result from depletion of central NA stores due to a reserpine-like effect of ammonia which is known to accumulate to millimolar concentrations in brain in ischemic liver failure. Impaired NA transport and the consequent increase in synaptic concentrations and increased stimulation of neuronal and astrocytic noradrenergic receptors could be implicated in the pathogenesis of the encephalopathy and brain edema characteristic of acute liver failure.

Acute Disease↗
PubMed2000

Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response.

Infection with EBV provides a unique opportunity to follow the human CD8(+) T cell response to a persistent, genetically stable agent from the primary phase, as seen in infectious mononucleosis (IM) patients, into long-term memory. This study focuses on the response to an immunodominant HLA-A2.01-restricted epitope, GLCTLVAML, from the EBV-lytic cycle Ag BMLF1. TCR analysis of the highly amplified primary response to this epitope revealed markedly oligoclonal receptor usage among in vitro-derived clones, with similar clonotypes dominant in all three IM patients studied. Direct staining of IM T cell preparations with the A2.01/GLCTLVAML tetramer linked this oligoclonal epitope-specific response with appropriate Vbeta subset expansions in the patients' blood. These patients were studied again >2 years later, at which time TCR analysis of in vitro-reactivated clones suggested that rare clonotypes within the primary response had now come to dominate memory. Five additional A2. 01-positive IM patients were studied prospectively for Vbeta subset representation within primary and memory epitope-specific populations as identified by tetramer staining. In each case, the primary response contained large Vbeta2, Vbeta16, or Vbeta22 components, and in three of five cases the originally dominant Vbeta was represented very poorly, if at all, in memory. We conclude 1) that an EBV epitope-specific primary response large enough to account for up to 10% CD8(+) T cells in IM blood may nevertheless be dominated by just a few highly expanded clonotypes, and 2) that with persistent viral challenge such dominant T cell clonotypes may be lost and replaced by others in memory.

Acute Disease↗
PubMed2000

Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease.

Acute chest syndrome (ACS) is the leading cause of death in sickle cell disease. Severe ACS often develops in the course of a vaso-occlusive crisis (VOC), but currently there are no predictors for its development. Secretory phospholipase A(2) (sPLA(2)), a potent inflammatory mediator, is elevated in ACS, and previous work suggests that sPLA(2) predicts impending ACS. We prospectively evaluated sPLA(2) concentration during 21 admissions for VOC; 6 of these patients went on to develop ACS. Elevation of sPLA(2) was detected all 6 patients 24 to 48 hours before ACS was clinically diagnosed. Adding the requirement for fever raised the specificity of sPLA(2) to 87% while retaining 100% sensitivity. These data indicate that sPLA(2) can be useful in alerting the clinician to patients with impending ACS. In addition, sPLA(2) may be useful for instituting early therapies to prevent or reduce the clinical morbidity of ACS.

Acute Disease↗